A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

Karen L. Reckamp; Vladislava O. Melnikova; Chris Karlovich; Lecia V. Sequist; D. Ross Camidge; Heather A. Wakelee; M. Pérol; Geoffrey R. Oxnard; Karena Kosco; Peter I. Croucher; Errin Samuëlsz; Cecile Rose T. Vibat; Shiloh Guerrero; Jennifer A. Geis; David Berz; Elaina Mann; Shannon Matheny; Lindsey Rolfe; Mitch Raponi; Mark G. Erlander; Shirish M. Gadgeel

doi:10.1016/j.jtho.2016.05.035

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

DNA derived from NSCLC tumors can be detected with high sensitivity in urine and plasma, enabling diagnostic detection and monitoring of therapeutic response from these noninvasive "liquid biopsy" samples.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Reckamp et al. (2016) studied this question.

synapsesocial.com/papers/69dc0d57a1150c2c259c7c7a https://doi.org/10.1016/j.jtho.2016.05.035

View Full Paper

Ask AI

Bookmark

Share

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

Ask about this paper

Abstract

Discussion

Cite This Study

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading